EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 17 Issue 2
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

Novartis’ Sandoz reportedly the target of $25B buyout bid from Carlyle and Blackstone

As Novartis reviews its generics business, the list of potential Sandoz suitors has grown. The deal could become one of the biggest generic industry acquisitions ever...
2 February 2022 Regional News Blackstone | Bloomberg
Continue Reading →
Regional News

Biogen’s Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst

During a January Q&A call with investors, Biogen chief Michel Vounatsos pressed Aduhelm supporters to fight the Centers for Medicare & Medicaid Services’ (CMS...
2 February 2022 Regional News Aduhelm | Biogen
Continue Reading →
Regional News

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties ...
2 February 2022 Regional News Amgen | drug
Continue Reading →
Regional News

Johnson & Johnson CEO: Consumer health split won’t interfere with our ‘more aggressive’ approach to M&A

For anyone playing a drinking game, taking a sip each time the phrase “the new Johnson & Johnson,” was uttered during the company’s fourth-quarter earnings call o...
26 January 2022 Regional News CEO | company
Continue Reading →
Regional News

Samsung Biologics outlines mRNA ambitions as “Super Plant” speeds toward completion

Samsung Biologics has been on an expansion sprint, with plans to speedily complete a so-called Super Plant already giving way to designs on follow-up facilities in th...
26 January 2022 Regional News biologics | mRNA
Continue Reading →
Regional News

Roche’s aim to widen Evrysdi’s label nabs speedy FDA review in young spinal muscular atrophy patients

Now poised for a speedy trip through the FDA's regulatory review, Roche’s oral challenger in spinal muscular atrophy (SMA) could soon pick up a nod to cover all patie...
26 January 2022 Regional News atrophy | disorder
Continue Reading →
Regional News

Argenx, already deep into its Vyvgart launch, charts course to become immunology ‘powerhouse’: CEO

Argenx is off to the races with the launch of its new med Vyvgart. With its first FDA-approved drug Vyvgart now rolling out, Argenx is charting a course to become an...
26 January 2022 Regional News Argenx | CEO
Continue Reading →
Regional News

FDA chides Eli Lilly for second misleading ad in 2 months, this time for diabetes blockbuster Trulicity

After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA's Office of Prescription Drug Promotion. The ...
26 January 2022 Regional News diabetes | drugmaker
Continue Reading →
Regional News

Deciphera details stomach cancer flop against Pfizer’s Sutent, cracking the door open for off-label use

Deciphera Pharmaceuticals recently took a serious hit to its billion-dollar hopeful cancer drug Qinlock. As the company undertakes a round of layoffs to deal with the...
26 January 2022 Regional News cancer | Deciphera
Continue Reading →
Regional News

Bayer leads $80M funding round for Cellino, betting on new cell therapy manufacturing platform

Since it was established in 2017, Cellino Biotech has offered an intriguing approach to stem cell therapy manufacturing, combining biology, laser physics, gene editin...
26 January 2022 Regional News Bayer | cell
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2025, All Rights Reserved – Powered by Teksyte